Latest News and Press Releases
Want to stay updated on the latest news?
-
Nationwide media tour conducted by Wacoal, in conjunction with D S Simon Media, discussing Fit for the Cure® Celebrates 25 Years: Wacoal hosts 400+ nationwide events supporting Susan G. Komen’s direct...
-
Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
-
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo...
-
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
-
ICPO und UroTeragLATAM gehen strategische Partnerschaft ein, um Theranostik für urologische Krebserkrankungen in Lateinamerika zu fördern
-
ICPO und UroTeragLATAM gehen strategische Partnerschaft ein, um Theranostik für urologische Krebserkrankungen in Lateinamerika zu fördern
-
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3...
-
OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
-
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
-
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...